Browse by Medical Category
The Boston NETT Group is a local consortium of hospitals dedicated to offering patients the most cutting edge clinical trials in neurologic emergencies.
The Boston Neurological Emergencies Treatment Trials (Boston NETT) Group is a team of local hospitals participating in a national, federally-funded research effort to develop new treatments for patients with acute diseases and injuries to the brain, spinal cord, and peripheral nervous system. Current NETT research studies aim to improve care for patients with stroke and seizures. Rapid diagnosis and early treatment are critical for improving outcomes in patients with neurologic emergencies, and the NETT will therefore conduct these studies on the front lines of emergency medicine, in cooperation with colleagues in neurology and neurocritical care.
This is an exciting opportunity to improve patient care in the emergency setting. We appreciate your interest, participation, and feedback. Welcome to the Boston NETT Group!
Joshua Goldstein, MD, PhDPrincipal InvestigatorBoston NETT
Visit the NETT National website
These clinical trials are currently enrolling patients at NETT sites nation-wide.
POINT – Platelet Oriented Inhibition in New TIATransient ischemic attacks (TIA) are common, with an estimated 250,000-350,000 occurring each year in the US. Patients with TIA often have rapid recovery of blood flow to the brain, which makes TIA different from completed stroke, where recovery is much longer. Many studies have shown that the short-term risk of stroke is high after TIA, particularly in the first few days, even in patients treated with aspirin, which is the current standard of care. Additional effective therapies in those with TIA could significantly reduce the overall burden of stroke if they are started right away. However, no large-scale research study has tested the safety or effectiveness of an acute treatment in patients with TIA. The POINT study aims to determine whether clopidogrel (Plavix) is effective in reducing the 90-day risk of stroke, myocardial infarction (heart attack), and ischemic vascular death when begun within 12 hours of TIA onset in patients taking aspirin.
You can also visit the POINT national study website for more information
SHINE – Stroke Hyperglycemia Insulin Network EffortSHINE aims to determine the most effective and safest way to control blood sugar levels in patients with an acute stroke and high blood sugar. Patients who enroll in SHINE will receive either insulin intravenous (IV) infusion (in the study treatment group) or saline (salt water) infusion with insulin injections (in the study control group) within 12 hours of the start of their stroke symptoms. Patients who enroll in the study will have their neurological outcomes measured 90 days after their stroke, using an exam called the modified Rankin Scale (mRS) score. To determine the effectiveness of the treatments, study doctors will compare the 90-day mRS scores of the study treatment and control groups. To determine the safety of the treatments, the study doctors will look at the rates of low blood sugar and worsening neurological outcomes that occur in both the study treatment and control groups.
You can also visit the SHINE national study website for more information
ESETT - The Established Status Epilepticus Treatment TrialESETT is aiming to determine which of 3 FDA approved medications is the best for treating emergency seizures that do not stop, a condition known as status epilepticus. Patients will receive either fos-phenytoin (also known as Cerebyx, or Prodilantin), valproic acid (also known as Depakote), or levetiracetam (also known as Keppra). ESETT will use a special set of rules called Exception From Informed Consent (EFIC) for emergency research.
For information about EFIC rules and the ESETT study at MGH, please click here:Mass General proposes new treatment trial for patients with severe seizures
If you would like to "opt out" or make sure you are not enrolled in this trial, please click here or contact us about it.
You can also visit the ESETT national study website for more information.
Center for Neurologic Emergencies5 Emerson Place, Suite 155Boston, MA 02114Phone: 617-726-4597BostonNETT@partners.org
Joshua N. Goldstein, MD, PhD, FACEP, FAHAAssociate Professor, Harvard Medical SchoolDirector, Center for Neurologic EmergenciesDepartment of Emergency MedicineMassachusetts General HospitalZero Emerson Place, Suite 3BBoston, MA email@example.comPhone: 617-724-3290
Chun Mei SuProgram Manager, Center for Neurologic EmergenciesProject Manager, Boston Neurologic Emergencies Treatment Trials (NETT) GroupDepartment of Emergency MedicineMassachusetts General HospitalFive Emerson Place, Suite 119DBoston, MA firstname.lastname@example.orgPhone: 617-726-4597
Back to Top